Jessica M. Grindheim

Papers

1

Total Citations

35

H-Index

1

About

Jessica M. Grindheim is a leading translational researcher in oncology, specializing in liquid biopsy biomarkers and immunotherapy response in non-small cell lung cancer (NSCLC). Her work focuses on harnessing dynamic circulating tumor DNA (ctDNA) to predict and monitor treatment outcomes, particularly in neoadjuvant settings. Her most-cited study, published in 2021, demonstrated that ctDNA dynamics during neoadjuvant atezolizumab therapy and surgery correlate with patient outcomes, providing a non-invasive tool to guide personalized treatment. This landmark work, with 35 citations, has advanced the understanding of real-time tumor evolution and immune checkpoint blockade efficacy. Grindheim’s contributions bridge molecular biology and clinical practice, offering a pathway to earlier intervention and improved survival. Her research is widely recognized for its potential to reduce unnecessary surgeries and optimize drug regimens, making her a key figure in the push toward precision oncology.

Research Focus

Key Achievements

1
H-Index
1
Papers
35
Total Citations
35
Avg Citations/Paper
🏆 Most Cited Paper
1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC
35 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 17

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago